Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start

por Facchinetti, Francesco, Friboulet, Luc
Publicado en Transl Lung Cancer Res (2018)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date

por Facchinetti, Francesco, Friboulet, Luc
Publicado en Lung Cancer (Auckl) (2019)

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis

por Guaitoli, Giorgia, Tiseo, Marcello, Di Maio, Massimo, Friboulet, Luc, Facchinetti, Francesco
Publicado en Transl Lung Cancer Res (2021)

Facts and new hopes on selective FGFR inhibitors in solid tumors

por Facchinetti, Francesco, Hollebecque, Antoine, Bahleda, Rastislav, Loriot, Yohann, Olaussen, Ken A, Massard, Christophe, Friboulet, Luc
Publicado en Clin Cancer Res (2019)

Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells

por Uzan Catherine, Témam Stéphane, Paturel Carine, Morel Yannis, Tsao Sai, Gourzones Claire, Friboulet Luc, Busson Pierre
Publicado 2010-06-01

Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells

por Friboulet, Luc, Gourzones, Claire, Tsao, Sai Wah, Morel, Yannis, Paturel, Carine, Témam, Stéphane, Uzan, Catherine, Busson, Pierre
Publicado 2010

Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer

por Katayama, Ryohei, Kobayashi, Yuka, Friboulet, Luc, Lockerman, Elizabeth. L., Koike, Sumie, Shaw, Alice T., Engelman, Jeffrey A., Fujita, Naoya
Publicado en Clin Cancer Res (2014)

Recurrent Overexpression of c-IAP2 in EBV-Associated Nasopharyngeal Carcinomas: Critical Role in Resistance to Toll-like Receptor 3-Mediated Apoptosis

por Friboulet, Luc, Pioche-Durieu, Catherine, Rodriguez, Sandrine, Valent, Alexander, Souquère, Sylvie, Ripoche, Hugues, Khabir, Abdelmajid, Tsao, Sai Wah, Bosq, Jacques, Lo, Kwok Wai, Busson, Pierre
Publicado 2008

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

por Gong, Bo, Kiyotani, Kazuma, Sakata, Seiji, Nagano, Seiji, Kumehara, Shun, Baba, Satoko, Besse, Benjamin, Yanagitani, Noriko, Friboulet, Luc, Nishio, Makoto, Takeuchi, Kengo, Kawamoto, Hiroshi, Fujita, Naoya, Katayama, Ryohei
Publicado en J Exp Med (2019)

Two novel ALK mutations mediate acquired resistance to the next generation ALK inhibitor alectinib

por Katayama, Ryohei, Friboulet, Luc, Koike, Sumie, Lockerman, Elizabeth L., Khan, Tahsin M., Gainor, Justin F., Iafrate, A. John, Takeuchi, Kengo, Taiji, Makoto, Okuno, Yasushi, Fujita, Naoya, Engelman, Jeffrey A., Shaw, Alice T.
Publicado en Clin Cancer Res (2014)

ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform

por Friboulet, Luc, Postel-Vinay, Sophie, Sourisseau, Tony, Adam, Julien, Stoclin, Annabelle, Ponsonnailles, Florence, Dorvault, Nicolas, Commo, Frédéric, Saulnier, Patrick, Salome-Desmoulez, Sophie, Pottier, Géraldine, André, Fabrice, Kroemer, Guido, Soria, Jean Charles, Olaussen, Ken André
Publicado 2013

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

por Gainor, Justin F., Tan, Daniel S.W., De Pas, Tomasso, Solomon, Benjamin J., Ahmad, Aziah, Lazzari, Chiara, de Marinis, Filippo, Spitaleri, Gianluca, Schultz, Katherine, Friboulet, Luc, Yeap, Beow Y., Engleman, Jeffrey A., Shaw, Alice T.
Publicado en Clin Cancer Res (2015)

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies

por Facchinetti, Francesco, Loriot, Yohann, Brayé, Floriane, Vasseur, Damien, Bahleda, Rastislav, Bigot, Ludovic, Barbé, Rémy, Nobre, Catline, Combarel, David, Michiels, Stefan, Italiano, Antoine, Smolenschi, Cristina, Tselikas, Lambros, Scoazec, Jean-Yves, Ponce-Aix, Santiago, Besse, Benjamin, André, Fabrice, Olaussen, Ken A., Hollebecque, Antoine, Friboulet, Luc
Publicado en Clin Cancer Res (2024)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

por Katayama, Ryohei, Sakashita, Takuya, Yanagitani, Noriko, Ninomiya, Hironori, Horiike, Atsushi, Friboulet, Luc, Gainor, Justin F., Motoi, Noriko, Dobashi, Akito, Sakata, Seiji, Tambo, Yuichi, Kitazono, Satoru, Sato, Shigeo, Koike, Sumie, John Iafrate, A., Mino-Kenudson, Mari, Ishikawa, Yuichi, Shaw, Alice T., Engelman, Jeffrey A., Takeuchi, Kengo, Nishio, Makoto, Fujita, Naoya
Publicado en EBioMedicine (2015)

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer

por Gainor, Justin F., Tseng, Diane, Yoda, Satoshi, Dagogo-Jack, Ibiayi, Friboulet, Luc, Lin, Jessica J., Hubbeling, Harper G., Dardaei, Leila, Farago, Anna F., Schultz, Katherine R., Ferris, Lorin A., Piotrowska, Zofia, Hardwick, James, Huang, Donghui, Mino-Kenudson, Mari, Iafrate, A. John, Hata, Aaron N., Yeap, Beow Y., Shaw, Alice T.
Publicado en JCO Precis Oncol (2017)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

por Mizuta, Hayato, Okada, Koutaroh, Araki, Mitsugu, Adachi, Jun, Takemoto, Ai, Kutkowska, Justyna, Maruyama, Kohei, Yanagitani, Noriko, Oh-hara, Tomoko, Watanabe, Kana, Tamai, Keiichi, Friboulet, Luc, Katayama, Kazuhiro, Ma, Biao, Sasakura, Yoko, Sagae, Yukari, Kukimoto-Niino, Mutsuko, Shirouzu, Mikako, Takagi, Satoshi, Simizu, Siro, Nishio, Makoto, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei
Publicado en Nat Commun (2021)

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

por Awad, Mark M., Katayama, Ryohei, McTigue, Michele, Liu, Wei, Deng, Ya-Li, Brooun, Alexei, Friboulet, Luc, Huang, Donghui, Falk, Matthew D., Timofeevski, Sergei, Wilner, Keith D., Lockerman, Elizabeth L., Khan, Tahsin M., Mahmood, Sidra, Gainor, Justin F., Digumarthy, Subba R., Stone, James R., Mino-Kenudson, Mari, Christensen, James G., Iafrate, A. John, Engelman, Jeffrey A., Shaw, Alice T.
Publicado 2013

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

por Friboulet, Luc, Li, Nanxin, Katayama, Ryohei, Lee, Christian C., Gainor, Justin F., Crystal, Adam S., Michellys, Pierre-Yves, Awad, Mark M., Yanagitani, Noriko, Kim, Sungjoon, Pferdekamper, AnneMarie C., Li, Jie, Kasibhatla, Shailaja, Sun, Frank, Sun, Xiuying, Hua, Su, McNamara, Peter, Mahmood, Sidra, Lockerman, Elizabeth L., Fujita, Naoya, Nishio, Makoto, Harris, Jennifer L., Shaw, Alice T., Engelman, Jeffrey A.
Publicado 2014

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

por Shaw, Alice T., Friboulet, Luc, Leshchiner, Ignaty, Gainor, Justin F., Bergqvist, Simon, Brooun, Alexei, Burke, Benjamin J., Deng, Ya-Li, Liu, Wei, Dardaei, Leila, Frias, Rosa L., Schultz, Kate R., Logan, Jennifer, James, Leonard P., Smeal, Tod, Timofeevski, Sergei, Katayama, Ryohei, Iafrate, A. John, Le, Long, McTigue, Michele, Getz, Gad, Johnson, Ted W., Engelman, Jeffrey A.
Publicado en N Engl J Med (2015)

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

por Kodack, David P., Farago, Anna F., Dastur, Anahita, Held, Matthew A., Dardaei, Leila, Friboulet, Luc, von Flotow, Friedrich, Damon, Leah J., Lee, Dana, Parks, Melissa, Dicecca, Richard, Greenberg, Max, Kattermann, Krystina E., Riley, Amanda K., Fintelmann, Florian J., Rizzo, Coleen, Piotrowska, Zofia, Shaw, Alice T., Gainor, Justin F., Sequist, Lecia V., Niederst, Matthew J., Engelman, Jeffrey A., Benes, Cyril H.
Publicado en Cell Rep (2017)